Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

T cell receptor gene therapy - Precigen Inc/Alaunos Therapeutics

Next Previous
Drug Profile

T cell receptor gene therapy - Precigen Inc/Alaunos Therapeutics

Alternative Names: Sleeping Beauty TCR-T; TCR T-cell therapy - Precigen Inc/Alaunos Therapeutics

Latest Information Update: 22 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Intrexon Corporation
  • Developer National Cancer Institute (USA); Precigen Inc; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; KRAS protein expression modulators; P53 gene modulators; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 08 Mar 2024 National Cancer Institute withdraws phase II trial in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA, due to difficulty with availability of GLP-grade reagents for manufacturing.(NCT04102436)
  • 02 Jun 2023 Updated adverse events and efficacy data from a phase I/II trial in Solid tumors presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
  • 03 Apr 2023 Precigen regains its exclusive rights from Alaunos Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top